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ABSTRACT
Glioblastoma is composed of dividing tumor cells, stromal cells and tumor 
initiating CD133+ cells. Recent reports have discussed the origin of the glioblastoma 
CD133+ cells and their function in the tumor microenvironment. The present work 
sought to investigate the multipotent and mesenchymal properties of primary highly 
purified human CD133+ glioblastoma-initiating cells. To accomplish this aim, we used 
the following approaches: i) generation of tumor subspheres of CD133+ selected 
cells from primary cell cultures of glioblastoma; ii) analysis of the expression of 
pluripotency stem cell markers and mesenchymal stem cell (MSC) markers in the 
CD133+ glioblastoma-initiating cells; iii) side-by-side ultrastructural characterization 
of the CD133+ glioblastoma cells, MSC and CD133+ hematopoietic stem cells isolated 
from human umbilical cord blood (UCB); iv) assessment of adipogenic differentiation 
of CD133+ glioblastoma cells to test their MSC-like in vitro differentiation ability; 
and v) use of an orthotopic glioblastoma xenograft model in the absence of immune 
suppression. We found that the CD133+ glioblastoma cells expressed both the 
pluripotency stem cell markers (Nanog, Mush-1 and SSEA-3) and MSC markers. 
In addition, the CD133+ cells were able to differentiate into adipocyte-like cells. 
Transmission electron microscopy (TEM) demonstrated that the CD133+ glioblastoma-
initiating cells had ultrastructural features similar to those of undifferentiated MSCs. 
In addition, when administered in vivo to non-immunocompromised animals, the 
CD133+ cells were also able to mimic the phenotype of the original patient’s tumor. 
In summary, we showed that the CD133+ glioblastoma cells express molecular 
signatures of MSCs, neural stem cells and pluripotent stem cells, thus possibly 
enabling differentiation into both neural and mesodermal cell types.
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INTRODUCTION
Glioblastoma has a polyclonal nature and is 
composed of dividing tumor cells, tumor initiating cells 
and stromal cells [1, 2]. Glioblastoma initiating cells, also 
called cancer stem cells (CSCs), are characterized as a 
CD133+ cell population within a tumor that possess the 
abilities to self-renew, generate neurospheres in vitro and 
reproduce the original tumor when administered in vivo 
to immunocompromised animals [3, 4, 5, 6, 7]. CD133+, 
a pentaspan membrane glycoprotein, has been used as a 
biomarker for glioblastoma initiating cells [3, 8, 9, 10, 11].
Recent reports have discussed the origin of the 
glioblastoma CD133+ cells and their functions in the 
tumor microenvironment [11, 12, 13, 14]. It is believed 
that glioblastoma CSCs arise through the neoplastic 
transformation of normal neuronal stem cells, because 
both cells are phenotypically CD133 positive. However, 
regulators of stem cell function (pluripotency markers) 
have also been implicated in cancer pathogenesis [15, 16, 
17, 18, 19]. Furthermore, the grade of the malignancy of 
glioblastoma and the efficiency of neurosphere formation 
increases according the expression level of Mush-1 [16].
The differentiation potential of glioblastoma 
CSCs is not restricted to neural lineages, and the CSCs 
can also differentiate into mesenchymal stem cells 
(MSCs) [20]. MSCs are multipotent stromal cells 
that differentiate into mesodermal lineages and have 
important immunomodulatory functions [21, 22]. MSCs 
are plastic-adherent under standard culture conditions and 
differentiate into osteoblasts, adipocytes and chondroblasts 
in vitro. They express CD29, CD105, CD73, CD44 and 
CD90, and lack expression of CD45, CD34, CD31, 
CD133, CD14, CD79a and HLA-DR cell surface markers.
Tso and coworkers [23] have observed that the 
immortalized glioblastoma cell lines (W-98, D-431, F-502 
and S-496) express surface antigen profiles similar to those 
of MSCs, because these cell lines express variable levels 
of CD44, CD90, CD105 and CD29, and do not express 
CD14, CD34 and CD31 cell surface markers.
In addition, forced expression of exogenous Nanog 
in MSCs leads these cells to differentiate into neural cells, 
even though this pluripotent embryonic marker is not 
expressed in neural stem cells [24].
It is unclear whether the CD133+ glioblastoma-
initiating cells are derived from transformed progenitor 
cells or whether the heterogeneity of glioblastoma cells 
results in activation of genes that elicit mesenchymal 
properties and contribute to the formation of the tumor 
stroma, which is essential for the growth and maintenance 
of glioblastomas [2, 25]. Secreted factors from all cells 
present in the tumor mass are able to diffuse through 
the peritumoral stroma, thereby creating a permissive 
microenvironment for malignant progression [26, 27]. In 
addition, the immunosuppressive characteristics of MSCs 
may protect tumor cells from attack by immune cells.
In the present study, we show that highly purified, 
neurosphere-forming CD133+ cells, obtained from human 
glioblastomas, express the cell marker profile characteristics 
of MSCs and the pluripotency markers, SSEA-1, Mush-
1 and Nanog. Furthermore, these cells are capable of 
differentiating into of mesodermal adipogenic-like cells. 
In addition, when administered in vivo to animals in the 
absence of immune suppression, the CD133+ cells are also 
able to mimic the phenotype of the original patient’s tumor, 
thus confirming that they have characteristics of CSCs.
RESULTS
The establishment of tumor subspheres of 
CD133+ selected cells from primary cell cultures 
of glioblastomas
Primary cell cultures were generated from 
glioblastoma mass samples (Figure 1A-a). These cells were 
homogenous, displayed fusiform format and were arranged 
in multidirectional bundles in culture (Figure 1A-a). Robust 
neurospheres were generated in vitro after glioblastoma cell 
dissociation (Figure 1A-b, c). As expected, glioblastoma 
neurospheres selected by using a CD133+ affinity column 
showed a higher content of CD133 positive cells (78%) 
(Figure 1B). After the dissociation of the neurospheres, the 
CD133+ cells were able to further generate subspheres with 
well-defined morphology (Figure 1A-d, e), whereas the 
negative fraction (the CD133- cells) was unable to generate 
subspheres (Figure 1A-f).
Immunophenotyping of the CD133+ glioblastoma 
cells by using flow cytometry
Flow cytometry analyses showed that the CD133+ 
cells highly expressed CD44 (94.0%) and CD90 (94.4%) 
(Figure 1D, 1E). In addition, a percentage of these cells 
also co-expressed CD44 and SSEA-3 (99.8%), as well as 
Mush-1 and Nanog (96.7%) (Figure 1C).
FACS analysis showed that the glioblastoma CD133+ 
cells expressed the typical mesenchymal markers CD29, 
CD44 (hyaluronic receptor), CD73, CD90, CD105 (endoglin) 
and CD166. In addition, our analysis showed that, similarly 
to MSCs, the CD133+ cells did not express high levels of 
either HLA-DR or the hematopoietic and vascular cell 
markers CD14, CD31, CD34, CD45 and CD106 (Figure 2).
Adipogenic differentiation of the CD133+ 
glioblastoma cells
We confirmed that the glioblastoma CD133+ 
adherent cells differentiated into adipocyte-like cells 
after 21 d by using Oil Red O staining (Figure 2E, 2F). 
Compared with the CD133- control cells (Figure 2A), these 
cells showed morphological changes, including a fusiform 
or fibroblastic morphology and peripheral basophilic 
nuclei due to the presence of many lipid droplets (Figure 
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2C–2F). Oil Red O staining was used to detect adipocyte-
like UC-MSCs as a positive control (Figure 2B).
Ultrastructural characterization of the 
CD133+ hematopoietic stem cells (UCBs) and 
glioblastoma cells
Using electron microscopy for ultrastructural 
analysis, we observed the presence of electron-dense 
granules on the cell surface of the CD133+ glioblastoma 
and UCB cells, thus demonstrating the presence of anti-
CD133 monoclonal antibodies bound to magnetics beads 
recognizing the CD133 membrane proteins on the cell 
surface (Figure 3B, 3C, 3H, 3I, 3L, 3M).
Electron micrographs showed that the CD133+ 
cells had a round morphology (Figure 3A, 3B, 3C, 3G, 
3I, 3K), with some discrete cytoplasmic projections 
(Figure 3A, 3B, 3H, 3M). The nuclei occupied the 
majority of the cells, and there was little cytoplasm 
in the CD133+ cells (Figure 3A, 3B, 3C, 3H, 3I, 3J). 
Clear nuclear envelopes and chromatin with numerous 
heterochromatic granules were also observed (Figure 
3B, 3C, 3H, 3J).
In the cytoplasm of the CD133+ cells, we observed 
the presence of numerous mitochondria, whose morphology 
varied from circular and electron dense to large and 
elongated with well-defined cristae (Figure 3D, 3I).
TEM detected the presence of smooth and rough 
endoplasmic reticulum and Golgi apparatus in CD133+ 
hematopoietic stem cells (UCB) (Figure 3B, 3D, 3F).
Electron-dense signals related to magnetic microbeads 
were observed in the cytoplasm of the CD133+ glioblastoma 
cells, which suggested that endocytosis (pinocytosis) 
facilitated microbead internalization (Figure 3G, 3L).
Both the UCB and glioblastoma CD133+ cells 
incorporated microbeads through their small cytoplasmic 
projections (Figure 3M), which resulted in clumps of the 
particles around the pynocytic vesicles (Figure 3E, 3L).
Figure 1: A, B. The establishment of human glioblastoma primary cell culture (A-a). Isolation of tumor neurospheres derived from 
glioblastoma primary cell culture. (A-b, c) Purification of glioblastoma cells from tumor subspheres using CD133 microbeads. 
Immunophenotypic characterization by using flow cytometry to evaluate the efficiency of magnetic cell separation for the antigenic marker, 
CD133 (78.0%). (B) CD133+ glioblastoma cells were able to further generate subspheres. Culture of glioblastoma subspheres (A-d, e) 
compared with the absence of subspheres obtained from CD133- fractions. (A-f) Representative figure of five glioblastoma samples at 400X 
magnification. C-F. Immunophenotyping of CD133+ glioblastoma cells by using flow cytometry. (C) First plot shows the isotype control. 
The second and third plots show the staining for CD44 and SSEA-3 (99.8%) and Nanog and MSh-1 (96.7%), respectively. (D) The first plot 
is an unstained sample, and the second plot shows the staining for CD44 and CD133 (94.0%). (E) The first plot is an unstained sample, and 
the second plot shows the staining for CD90 and CD133 (94.4%). (F) Red (isotype control); Blue (stained sample).
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Figure 2: The increased expression of the mesenchymal markers (CD29, CD44, CD73, CD90, CD105 and CD166) 
and low or no expression of the MHC class I antigens, HLA-DR and the hematopoietic/vascular cells markers (CD14, 
CD31, CD34, CD45 and CD106) on the CD133+ glioblastoma cells; red: isotype control; blue: stained sample. A-F. 
The adipogenic differentiation of the MSCs and glioblastoma CD133+ cells as detected by the formation of intra-cytoplasmic lipid 
droplets stained with Oil Red O (black arrow). (A) CD133- (control). (B) Adipogenic differentiation of the MSCs. (C-F) The adipogenic 
differentiation of the CD133+ glioblastoma cells. (A, B) Magnification: 200X. (C-F) Magnification: 600X.
Figure 3: (A-F) TEM of the CD133+ hematopoietic stem cells (UCB). n = nucleus, c = cytoplasm, mi = mitochondria, rer = 
rough endoplasmic reticulum, ser = smooth endoplasmic reticulum, pv = pinocytic vesicles, li = lipid droplets, gc = Golgi complex, ly = 
lysosomes, arrow = electron-dense granules or magnetic beads. TEM of the CD133+ glioblastoma stem cells. n = nucleus, c = cytoplasm, 
mi = mitochondria, rer = rough endoplasmic reticulum, pv = pinocytic vesicles, arrow = electron-dense granules or magnetic beads. Scale: 
A-C, G-J. 5.0 μm; F, K. 2.0 μm; D, E. 1.0 μm; L, M. 0.5 μm.
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Ultrastructural characterization of the UC-MSCs
Ultrastructural analysis of the MSCs showed a spindle 
morphology with cytoplasmic extensions (Figure 4D) and 
oval nuclei (Figure 4B, 4C, 4E) containing dispersed 
chromatin and visible nucleoli (Figure 4B, 4C, 4E).
Figure 4B shows the irregular nucleus with a 
clear nucleolus, thus suggesting high levels of protein 
synthesis in the nuclear process. The cytoplasm of 
these cells showed well-developed rough endoplasmic 
reticulum, and circular and lamellar (Figure 4B, 4C, 4E, 
4F) as well as elongated or round mitochondria (Figure 
4A, 4B).
Detection of multimodal iron oxide nanoparticles 
conjugated to Rhodamine-B (MION-Rh) in the 
CD133+ glioblastoma cells
A qualitative evaluation of the intracellular 
distribution of MION-Rh in CD133+glioblastoma cell 
was performed by using fluorescence microscopy with a 
Rh-B filter (530 nm and 550 nm). The presence of red 
Figure 4: TEM micrographs of the UC-MSCs. n = nucleus, nu = nucleolus, c = cytoplasm, mi = mitochondria, rer = rough 
endoplasmic reticulum, v = vacuoles, ce = cytoplasmic expansions. Scale: A-C, E. 5.0 μm; D, F. 0.5 μm.
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fluorescence showed that MION-Rh was internalized as 
intracellular granules (Figure 5A).
The in vivo detection of glioblastoma tumor 
growth by using fluorescence, X-ray and 
histopathological analysis
Tumors were generated after stereotaxic 
implantation of glioblastoma CD133+ cells labeled with 
MION-Rh (Figure 5B), and the progression of tumor 
growth was monitored by using combined fluorescence 
and X-ray detection (Figure 5C, 5D). On day 28, visible 
tumors were detected with fluorescence staining (Figure 
5D1 and 5F) and Prussian blue staining (Figure 5E).
Histopathological examination showed that 
the tumors exhibited high cellularity, nuclear atypia 
(Figure 6A, 6B, 6C), invasiveness (Figure 6C, 6D, 
6E, 6F) and vascular proliferation (Figure 6G, 6H). 
Immunohistochemical analysis for GFAP confirmed tumor 
formation originated in the glia (Figure 6B, 6D, 6H), and 
Ki67 detection revealed a high number of cycling cells in 
the tumor tissue (Figure 6E, 6F).
DISCUSSION
The present work demonstrated the mesenchymal 
stem cell-like properties of CD133+ glioblastoma-
initiating cells by examining the pluripotency, stemness 
characteristics and differentiation potential of CD133+ 
glioblastoma cells.
We described a successful method for isolation 
of a CD133+ cell population and the establishment of 
glioblastoma neurospheres from primary cultures. The 
neurospheres demonstrated a higher concentration 
of CD133+ cells (78%), and the enriched CD133+cell 
fraction was able to further generate clonogenic cells 
or subspheres with well-defined morphology, thus 
highlighting the importance of the CD133 marker 
in the selection and enrichment of these cells from 
glioblastoma neurospheres.
The immunophenotypic profile of the CD133+ cells 
showed that these cells expressed high levels of CD44 and 
CD90 cell-surface glycoproteins. Recently, the CD90 stem 
cell marker has been identified as a prognostic marker 
for high-grade gliomas, and CD44 has been shown to 
be a potential metastatic marker [28, 29]. Bahnassy and 
colleagues [30] have shown that aberrant expression of 
cancer stem cell markers (CD133, CD90 and CD44) 
contributes to tumor progression. In fact, according to 
our in vivo results, the CD133+/CD90+/CD44+ tumor 
stem cells may be responsible for dissemination of 
glioblastoma, which leads to reduced patient survival 
[30]. The glioblastoma CD133+ cells also co-express 
significant levels of SSEA-3 (stage-specific embryonic 
antigen 3), Mush-1 (neural stem cell marker) and Nanog 
(transcriptional regulator involved proliferation and self-
renewal of embryonic stem (ES) cells). The expression 
of SSEA-3 and Nanog demonstrate that the CD133+ cells 
are multipotent, whereas expression of Mush-1 indicates 
their neuronal origin. Therefore, CD133+, CD90+, SSEA-
3, Nanog and Mush-1 may be used as enrichment markers 
for glioblastoma CSCs [13, 16, 24, 29, 30].
Tso and colleagues [23] have observed that some 
immortalized glioblastoma cell lines (W-98, D-431, F-502, 
and S-496) express molecular markers that are associated 
with MSCs. In addition, these glioblastoma cell lines can 
Figure 5: A. Fluorescence detection of MION-Rh labeling in the CD133+ glioblastoma cells. Magnification: 600X. B. Stereotaxic 
implantation of the MION-Rh labeled CD133+ glioblastoma cells labeled in the tumor experimental models. C. Ex vivo brain imaging; arrow 
= region of the tumor. D. In vivo detection of the glioblastoma using combined fluorescence and X-ray tomography. D1. Fluorescence image 
detail. E. Immunohistochemical analysis for Prussian blue staining of the tumor. F. Fluorescence assay of the tumor. (E) Magnification: 
400X. (F) Magnification: 600X.
Oncotarget40552www.impactjournals.com/oncotarget
be induced to differentiate into multiple mesenchymal 
lineage-like cell types. In this study, we observed that the 
CD133+ glioblastoma cells expressed molecular markers 
associated with the MSC phenotype (CD29, CD44, CD73, 
CD90, CD105 and CD166). Furthermore, the CD133+ 
cells were also able to differentiate into adipocyte-like 
cells. These cells had fusiform or fibroblastic morphology 
and peripheral basophilic nuclei due to the presence of 
many lipid droplets, characteristics similar to those of 
MSCs.
Figure 6: A, C, G. Hematoxylin and eosin staining. B, D, H. Immunohistochemical analysis for GFAP. E, F. Immunohistochemical analysis 
for Ki67. Arrow = vascular proliferation. Arrow a = tumor area. (A, B, C, E, G, H) Magnification: 400X. (D, F) Magnification: 600X.
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To our knowledge, this is the first study to provide 
the ultrastructural characterization of CD133+ cells from 
two different sources: hematopoietic stem cells (UCB) and 
glioblastomas. Both the UCB and glioblastoma CD133+ 
cells included anti-CD133 monoclonal antibodies bound 
to magnetic beads, which were observed as electron-
dense granules on the cell surface and were internalized 
by pynocytic vesicles. The ultrastructural analysis of 
CD133+ hematopoietic stem cells [31] served as a control 
for the highly purified glioblastoma CD133+ cells from the 
primary cell culture.
Our ultrastructural analysis confirmed that we 
isolated glioblastoma CSCs expressing the marker CD133. 
We observed that these cells possessed ultrastructural 
features similar to those of undifferentiated MSCs, such 
as spindle morphology with cytoplasmic extensions.
After extensive characterization of the CD133+ 
glioblastoma cells, we demonstrated that these cells 
recapitulated the phenotype of the original patient’s 
tumor, after the cells were administered in vivo to 
non-immunocompromised animals. Histopathological 
examinations of the tumor revealed high cellularity 
of glial origin, nuclear atypia, vascular proliferation, 
invasiveness and a high Ki-67 proliferative index. These 
findings demonstrate that we were able to isolate stem 
cells responsible for tumorigenesis, thus demonstrating a 
correlation between the prognostic value and the expression 
of the stem cell marker CD133 in glioblastoma [31].
In this study, we showed that the CD133+ 
glioblastoma cells formed intracranial tumors in rats 
that were not immunocompromised, thus suggesting the 
involvement of local immunoresistance mechanisms or 
tumor-specific immunity avoidance through different 
mechanisms involving both the intrinsic properties of the 
glioma cells and microenvironmental factors [32, 33]. 
Notably, MSCs are able to avoid the immune response in 
allogenic and xenotransplants; however, the mechanism 
has not been fully elucidated but parallels tumor evasion. 
The MSC-like properties observed in the CD133+ cell 
population from this study may be important to sustain 
tumor growth and malignant progression, which is 
affected by the tumor microenvironment created by the 
non-neoplastic stroma composed of inflammatory and 
connective tissue components [34, 35, 36, 37, 38].
In summary, we showed that CD133+ glioblastoma-
initiating cells express cell surface markers characteristic 
of MSCs. It is likely that these markers play a role in the 
biological and pathological behavior of the glioblastoma 
cells in vivo during malignant progression. These findings 
may interfere the development of effective treatment 
strategies that are commonly used for MSC-initiated 
tumors but are not currently considered for glioblastoma. 
Consequently, we suggest that the MSC-like properties 
of CD133+ glioblastoma-initiating cells confer pro-
angiogenic, anti-apoptotic and immunomodulatory 
characteristics that may sustain tumor growth even in 
animals that are not immunocompromised. Therefore, 
tumor progression may be directed by reciprocal 
interaction between tumor stromal cells and tumor 
cells to create an appropriate environment for tumor 
aggressiveness. Future studies are necessary to elucidate 
the function of the MSC traits found in the CD133+ 
glioblastoma CSCs in the genesis, invasiveness and 
progression of glioblastomas.
MATERIALS AND METHODS
In this study, we analyzed five samples of human 
primary glioblastomas obtained from adult patients 
undergoing resection at the Department of Neurology and 
Neurosurgery, Escola Paulista de Medicina - Universidade 
Federal de São Paulo (EPM-UNIFESP). All patients gave 
informed consent for participation in the study (UNIFESP 
- Ethical Committee).
Establishment of the glioblastoma primary cell 
culture
Fresh glioblastoma samples were washed and minced 
in phosphate-buffered saline (PBS) (1X); this was followed 
by enzymatic dissociation with collagenase-I 0.3% (Sigma-
Aldrich). The isolated cells were resuspended in Dulbecco’s 
Modified Eagle’s Medium-Low Glucose (DMEM-LG, 
Gibco/Invitrogen Corporation) supplemented with 200 mM 
of L-Glutamine, Antibiotic–Antimycotic (10,000 U/mL of 
sodium penicillin, 10,000 μg/mL of streptomycin sulfate and 
25 μg/mL of amphotericin B; Thermo Fisher Scientific), and 
10% Fetal Bovine Serum (Thermo Fisher Scientific). The 
cells were seeded in 25-cm2 culture flasks and maintained at 
37°C with 5% CO2. The culture medium was changed every 
other day.
Glioblastoma-derived neurosphere culture
The glioblastoma cells obtained in the primary culture 
described above were resuspended in “tumor brain stem 
cell medium” (Dulbecco’s Modified Eagle’s Medium/F12; 
Thermo Fisher Scientific), supplemented with N-2 (Thermo 
Fisher Scientific), epidermal growth factor (EGF, 20 ng/mL; 
Thermo Fisher Scientific), basic fibroblast growth factor 
(bFGF, 20 ng/mL; Thermo Fisher Scientific), leukemia 
inhibitory factor (LIF, 10 ng/μl; EMD Millipore) and B-27 
(1:50; Thermo Fisher Scientific). Viable cells were seeded 
in 24-well plates at a density of 2x104 cells/cm2. The cells 
were maintained in a humidified incubator (Thermo Fisher 
Scientific, Waltham, MA) with 5% CO2 at 37°C, and the 
culture medium was changed every three days.
Purification of the glioblastoma cells with CD133 
microbeads and preparation of the tumor 
subspheres
The neurosphere colonies were dissociated using 
StemPro Accutase (Thermo Fisher Scientific) and 
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maintained at room temperature for 10 min. The cells 
were labeled with CD133 magnetic microbeads (MACS; 
Miltenyi Biotec) and selected with an affinity column 
according to the manufacturer’s instructions (Miltenyi 
Biotec). To verify the separation efficiency, the CD133+ 
cells were stained with CD133/2PE and evaluated by 
using flow cytometry (FACSAria, BD Biosciences, San 
Jose, CA) and analyzed with FACSDiva software (BD 
Biosciences, San Jose, CA) [39].
The CD133+ selected and CD133- depleted cell 
populations were resuspended in Dulbecco’s Modified 
Eagle’s Medium/F12 and seeded in 24-well plates at a 
density of 1x103 cells/cm2. Subsphere formation was 
observed in only the CD133+cells and was documented 
by using phase-contrast microscopy (Olympus IX51) 
[39].
Immunophenotyping of the CD133+ glioblastoma 
cells by using flow cytometry
We analyzed the cell-surface expression of 
specific markers in the CD133+ cells subspheres by using 
commercially available monoclonal antibodies according 
to the manufacturer’s instructions. Briefly, subspheres were 
harvested with StemPro Accutase Cell Dissociation Reagent 
(Thermo Fisher Scientific, Carlsbad, CA) and washed with 
PBS (pH=7.4). Next, the cells were stained with monoclonal 
antibodies and incubated in the dark for 30 min at room 
temperature. For intracellular staining, the cells were fixed 
(FACS Lysing Solution, BD Biosciences) and permeabilized 
(Permeabilization Solution 2, BD Biosciences, San Jose, 
CA). Human monoclonal antibodies against the following 
were used: CD133/2 PE (clone: 133/2; Miltenyi Biotec, 
Bergisch Gladbach, Germany), Nanog FITC, CD44 PE, 
Msh-1 PE, SSEA-3 FITC, CD90 APC and CD44 PerCP-
Cy5.5 (all from BD Biosciences, San Diego, CA). We also 
used the related isotypes or fluorescence minus one (FMO) 
controls. The data were acquired with a FACSAria flow 
cytometer (BD Biosciences, San Jose, CA) and analyzed by 
using FACSDiva (BD Biosciences, San Jose, CA) or FlowJo 
software (Tree Star, Ashland, OR).
The expression of the typical mesenchymal markers 
in the glioblastoma CD133+ cells were analyzed by using 
CD29 PE, CD44 PE, CD73 PE, CD90 APC, CD105 PE 
and CD166 PE antibodies from BD Biosciences (San 
Diego, CA) using methods previously described in Sibov 
and colleagues [40].
Adipogenic differentiation capacity of the 
CD133+ glioblastoma cells
CD133+ glioblastoma cells were subjected to 
adipogenic differentiation in vitro according to previously 
described methods by Sibov and colleagues [25]. Briefly, 
the cells were plated at a density of 103 cells/cm2 in a 
6-well culture plate. When the cells reached approximately 
80% confluence, adipogenic induction medium was added 
and changed every other day until 21 d. The adipogenic 
culture medium contained: 10 μg/mL of insulin (Sigma-
Aldrich), 100 μM of indomethacin (Sigma-Aldrich), 
1μM of dexamethasone (Sigma-Aldrich), and 100 μg/
mL of 3-isobutyl-1-methyl-xanthine (Sigma-Aldrich) in 
Minimum Essential Medium Alpha Medium (Thermo 
Fisher Scientific) with 10% fetal bovine serum. After 21 d, 
the cells were fixed with 4% paraformaldehyde and stained 
with 0.3% Oil Red O stain (Sigma-Aldrich), according to 
methods previously described by Sibov and colleagues 
[41]. The morphology of the cells was assessed with an 
IX51 inverted microscope (Olympus, Tokyo, Japan).
CD133+ glioblastoma cell labeling with 
multimodal iron oxide nanoparticles conjugated 
to Rhodamine-B (MION-Rh)
Approximately 103 CD133+ glioblastoma cells 
were plated in 24-well plates. The cells were incubated 
overnight (for approximately 18 h at 37°C with 5% CO2) 
in Dulbecco’s Modified Eagle’s Medium/F12 and 40 μg 
Fe/mL MION-Rh. After incubation, the culture medium 
solution was removed, and the cells were washed twice 
with PBS (1X) to remove the extracellular MION-Rh. The 
labeled cells were treated with 0.25% TrypLE Express and 
then harvested and manually counted using 0.4% Trypan 
Blue staining (Thermo Fisher Scientific).
Intracellular detection of MION-Rh in the 
labeled CD133+ glioblastoma cells
The CD133+ glioblastoma cells were washed twice 
with PBS (1X) and fixed with 4% paraformaldehyde. The 
cell nuclei were labeled with diamidino-2-phenylindole 
(DAPI, Sigma-Aldrich) and analyzed with an IX51 
fluorescence microscope (Olympus, Tokyo, Japan) with a 
Rh-B filter (530 nm and 550 nm) to detect the MION-Rh
Isolation and culture of umbilical cord-derived 
MSCs (UC-MSC)
Five umbilical cord and umbilical cord blood 
samples were collected with the informed consent of 
the donor’s mother, with protocol approval from the 
ethics committee for research at the HSP, UNIFESP, 
São Paulo, Brazil. The samples were processed and 
cultured for 21 d, with a medium change every other 
day, according to previously described methods by 
Sibov and colleagues [40]. After 3 weeks, UC-MSCs 
with fibroblast morphology were the dominant cells in 
the culture. UC-MSCs were differentiated into three 
mesodermal lineages and characterized by using flow 
cytometry. All experiments were performed with cells 
in the fourth passage.
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Selection of CD133+ hematopoietic stem cells 
from human umbilical cord blood (UCB)
UCB was collected by puncturing the umbilical cord 
vein at the moment of birth (after the cord was cut) using 
sterile equipment and 250 mL blood bags containing 2 
mL of anticoagulant. The volume of the collected blood 
ranged between 70 and 120 mL. A sample of 80 μL of 
blood was separated for further cell count. The blood 
was then diluted (1:2) in RPMI culture medium (Thermo 
Fisher Scientific), and the lymphomononuclear cells were 
separated by using Ficoll-PaqueTM Plus (GE Healthcare) 
at a 1:3 density gradient (Lehner; Holter, 2002). The 
cells were centrifuged at 400 xg for 35 min, and the 
fraction containing the lymphomononuclear cells was 
isolated using a 10 mL pipette and then washed in RPMI 
medium. The CD133+ cell population was purified by 
using MiniMACS microbeads affinity chromatography 
using anti-CD133 bound to magnetic beads (Miltenyi 
Biotec). The cells were filtrated with a 30 μm nylon 
filter, and the number of cells was determined by the cell 
count in an automatic counter (Coulter). The cells were 
centrifuged (400 xg for 5 min) and resuspended in 300 μL 
of a PBS solution containing 2 mM of EDTA and 0.5% 
BSA. For each 108 cells, 100 μL of FcR blocker and 100 
μL of magnetic micro-spheres with CD133+ antibodies 
(6°C) were added. The labeled cells were separated on 
a chromatography column to isolate the CD133+ cells 
according to previously described methods by Pavon and 
colleagues [42].
Transmission electron microscopy (TEM) of the 
CD133+ glioblastoma cells, CD133+ hematopoietic 
stem cells (UCBs) and the UC-MSCs
The cells were fixed in 1% glutaraldehyde and 
0.2 M of cacodylate buffer for 2 h at 4°C, according to 
previously described methods for TEM by Pavon and 
colleagues [42].
Stereotaxic implantation of the CD133+ 
glioblastoma cells labeled with MION-Rh
The present work was conducted according to the 
regulations of the Ethics in Animal Research Committee 
of the UNIFESP. The animals (n=5; male Wistar rats) were 
anesthetized with ketamine (55 mg/kg) and xylazine (11 
mg/kg). The hair was then removed from the top of the 
head, and the head was fixed in the stereotaxic apparatus 
(Stoelting®, model 51700). A skin incision was made on 
the dorsal region of the skull, the periosteum was removed 
and a trepanation of the bone cap was made using a dental 
drill. The implantation position was determined and 
marked in the bone according to Swanson’s stereotaxic 
guidelines at the following coordinates: 6.0 mm 
anteroposterior, 4.5 mm mediolateral and a depth of 1.8 
mm. A Hamilton syringe was used to implant 104 CD133+ 
glioblastoma cells resuspended in10 μL of culture medium 
into the right caudate putamen (CPu). The cells were 
slowly injected over a 10 min period. To avoid drawing the 
injected solution back into the needle, the syringe was kept 
in position for an additional 2 min before slowly being 
withdrawn from the brain. The bone was then reassembled 
using bone wax, and the skin was sutured using cotton 
thread.
Analysis of tumor development by using in vivo 
imaging and histopathological analysis
The FX PRO imaging system was used to obtain 
X-ray and fluorescence images. The animals were placed 
in dorsal recumbency and remained anesthetized with 
inhalational anesthetic consisting of 2% isoflurane with 
oxygen (2 L/min) during the image acquisition. We first 
acquired X-ray images of the skull. Next, fluorescence 
images of the MION-Rh labeled cells were obtained at an 
excitation of 540 nm and an emission of 585 nm, and the 
images were analyzed using multiplex-located software.
We performed immunohistochemical staining 
for glial fibrillary acidic protein (GFAP) and the Ki67 
proliferation marker, and Prussian blue staining for 
MION-Rh.
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